Abstract: The present disclosure relates to methods for the treatment of multiple myeloma in patients who have one or more cytogenetic alterations. In particular, the disclosure provides methods for treatment of multiple myeloma in patients who have one or more cytogenetic alternations by administering to a patient a treatment regimen comprising a proteasome inhibitor or a pharmaceutically acceptable salt, stereoisomeric or tautomeric form thereof if said patient is identified as a likely responder to the treatment regimen by assessing the presence of said cytogenetic alterations.

Abstract: Disclosed herein are markers whose mutational status is associated with sensitivity to treatment with NAE inhibitors. Mutational status is determined by measurement of characteristics of markers associated with the marker genes. Compositions and methods are provided to assess markers of marker genes to predict response to NAE inhibition treatment.

Abstract: The present disclosure relates to methods for the treatment of multiple myeloma in patients who have one or more cytogenetic alterations. In particular, the disclosure provides methods for treatment of multiple myeloma in patients who have one or more cytogenetic alternations by administering to a patient a treatment regimen comprising a proteasome inhibitor or a pharmaceutically acceptable salt, stereoisomeric or tautomeric form thereof if said patient is identified as a likely responder to the treatment regimen by assessing the presence of said cytogenetic alterations.

Abstract: The present invention is directed to the identification of predictive markers that can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to treatment. In particular, the present invention is directed to the use of certain individual and/or combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen. Thus, by examining the expression levels of individual predictive markers and/or predictive markers comprising a marker set, it is possible to determine whether a therapeutic agent, or combination of agents, will be most likely to reduce the growth rate of tumors in a clinical setting.

Abstract: The present invention provides a method of treating cancer with a proteasome inhibitor. The invention also provides a method of treating a patient with cancer based on elevated expression levels of NF?B, as measured by a H-score of the patients tumor sample using a NF?B p65 IHC assay. The invention also provides a method of determining whether to treat a patient with a proteasome inhibitor based on the level of NF?B p65 in the patient's tumor sample.

Abstract: Disclosed herein are markers whose mutational status is associated with sensitivity to treatment with NAE inhibitors. Mutational status is determined by measurement of characteristics of markers associated with the marker genes. Compositions and methods are provided to assess markers of marker genes to predict response to NAE inhibition treatment.

Abstract: The present invention provides a method of treating nasopharyngeal cancer with a proteasome inhibitor of formula (7). The invention also provides a method of treating a patient with nasopharyngeal cancer based on elevated expression levels of NFkB, as measured by a H-score of the patient's nasopharyngeal cancer tumor sample using a “NFkB p65 IHC assay. The invention also provides a method of determining whether to treat a patient with the compound of formula (/) based on the level of NFkB p65 in the patient's nasopharyngeal cancer tumor sample.

Abstract: Disclosed herein are markers whose mutational status is associated with sensitivity to treatment with NAE inhibitors. Mutational status is determined by measurement of characteristics of markers associated with the marker genes. Compositions and methods are provided to assess markers of marker genes to predict response to NAE inhibition treatment.

Abstract: Disclosed herein are chromosomal loci associated with clinical outcome to treatment for multiple myeloma. Genome-wide changes observed in myeloma relate to prognosis and treatment response to a proteasome inhibitor. Compositions and methods are provided to assess DNA copy number at corresponding to markers of loci and genes found thereon which are amplified or deleted, overexpressed or underexpressed in myeloma tumors to predict response to treatment, time-to-progression and survival upon treatment.

Abstract: The present invention provides a method of treating cancer with a proteasome inhibitor. The invention also provides a method of treating a patient with cancer based on elevated expression levels of NF?B, as measured by a H-score of the patients tumor sample using a NF?B p65 IHC assay. The invention also provides a method of determining whether to treat a patient with a proteasome inhibitor based on the level of NF?B p65 in the patient's tumor sample.

Abstract: The present invention is directed to the identification of predictive markers that can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to treatment. In particular, the present invention is directed to the use of certain individual and/or combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen. Thus, by examining the expression levels of individual predictive markers and/or predictive markers comprising a marker set, it is possible to determine whether a therapeutic agent, or combination of agents, will be most likely to reduce the growth rate of tumors in a clinical setting.

Abstract: Disclosed herein are markers associated with sensitivity to treatment with proteasome inhibitors. Sensitivity is observed when RAS gene is wild type in tumor cells.

Abstract: Disclosed herein are markers whose mutational status is associated with sensitivity to treatment with NAE inhibitors. Mutational status is determined by measurement of characteristics of markers associated with the marker genes. Compositions and methods are provided to assess markers of marker genes to predict response to NAE inhibition treatment.

Abstract: Disclosed herein are markers whose mutational status is associated with sensitivity to treatment with NAE inhibitors. Mutational status is determined by measurement of characteristics of markers associated with the marker genes. Compositions and methods are provided to assess markers of marker genes to predict response to NAE inhibition treatment.

Abstract: The present invention is directed to the identification of predictive markers that can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to treatment. In particular, the present invention is directed to the use of certain individual and/or combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen. Thus, by examining the expression levels of individual predictive markers and/or predictive markers comprising a marker set, it is possible to determine whether a therapeutic agent, or combination of agents, will be most likely to reduce the growth rate of tumors in a clinical setting.

Abstract: Disclosed herein are chromosomal loci associated with clinical outcome to treatment for multiple myeloma. Genome-wide changes observed in myeloma relate to prognosis and treatment response to a proteasome inhibitor. Compositions and methods are provided to assess DNA copy number at corresponding to markers of loci and genes found thereon which are amplified or deleted, overexpressed or underexpressed in myeloma tumors to predict response to treatment, time-to-progression and survival upon treatment.